Mental Disorder Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The mental disorder treatment market size was valued at USD 71.45 billion in 2025 and is estimated to grow from USD 76.92 billion in 2026 to reach USD 111.26 billion by 2031, at a CAGR of 7.66% during the forecast period (2026-2031). This report is segmented by Treatment Modality (Pharmacological Treatment, and More), Disorder Type (Depressive, Anxiety, Schizophrenia, and More), Route of Administration (Oral, Injectables, and More), End User (Hospitals, Psychiatry Facilities, Outpatient Clinics, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Mental Disorder Treatment Market Trends and Insights

Novel Mechanisms for Treatment-Resistant Disorders

The mental disorder treatment market is expected to broaden treatment options for patients who do not respond to conventional antidepressants. In January 2025, the FDA approved SPRAVATO nasal spray as a monotherapy for adults with treatment-resistant depression, supported by Phase IV data showing Week 4 remission in 22.5% of patients versus 7.6% receiving placebo. At the time of approval, more than 140,000 patients across 77 countries are expected to have used the therapy. In January 2026, Neurolief received FDA Premarket Approval for ProlivRx, an at-home brain neuromodulation therapy for adults with major depressive disorder who have failed at least one prior antidepressant. These developments are expected to strengthen outpatient and home-based treatment options.

Rising Diagnosis and Treatment Uptake

Improved disease recognition is expected to expand the patient base in the mental disorder treatment market. Digital screening across primary care settings and employer-supported services can accelerate diagnosis and treatment initiation. The attention-deficit/hyperactivity disorder segment is forecast to grow at a CAGR of 9.71% from 2026 to 2031, driven by increased diagnosis among historically underidentified adults. The United States is estimated to have an estimated 21 million adults living with major depressive disorder in 2025. In January 2025, Neurocrine Biosciences initiated Phase 3 registrational studies for osavampator as an adjunctive treatment for adults with major depressive disorder. Treatment uptake will depend on both diagnostic infrastructure and medicine availability.

Generic Erosion and Loss of Exclusivity

Generic competition reduces branded medicine revenue and constrains research funding in the mental disorder treatment market. The impact is highest for established antidepressants and antipsychotics facing loss of exclusivity. Companies increasingly prioritize differentiated products that address unmet clinical needs. Larger pharmaceutical groups can manage development risks more effectively than smaller specialty companies, while acquisitions gain importance when internal programs fail or generic competition intensifies.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Mental Health Coverage and Reimbursement
• Integration of Mental Health Into Primary Care
• Fragmented Reimbursement for Psychotherapy and Digital Treatments

Segment Analysis

Pharmacological treatment accounted for 61.40% of the mental disorder treatment market size by treatment modality in 2025. Its leading position reflects the broad use of antidepressants, antipsychotics, mood stabilizers, anxiolytics, and stimulants, supported by established formularies and prescriber familiarity. CAPLYTA received FDA approval as an adjunctive therapy with antidepressants for adults with major depressive disorder in November 2025. The therapy also received approval in April 2026 for schizophrenia relapse prevention, demonstrating a 63% reduction in relapse risk versus placebo and 84% of patients remaining relapse-free over six months.

Psychotherapy and behavioral treatment is forecast to grow at a CAGR of 10.55% between 2026 and 2031. Digital delivery expands therapist-supported care beyond traditional clinic capacity, while integrated and community-based models support coordinated behavioral care. In September 2025, BrainsWay received FDA clearance for an accelerated Deep TMS protocol for major depressive disorder. The protocol may shorten the standard four-week course and improve throughput at outpatient treatment centers. The late-2025 approval of Flow FL-100 and the January 2026 approval of ProlivRx support home-based neuromodulation beyond conventional hospital settings.

Depressive disorders represented 42.04% of the mental disorder treatment market size by disorder type in 2025. The segment has substantial treatment demand and a broad portfolio of branded and generic medicines, with an estimated 21 million adults in the United States living with major depressive disorder in 2025. The 2025 SPRAVATO monotherapy approval created a treatment option for adults with treatment-resistant depression. Anxiety disorders, schizophrenia spectrum disorders, and bipolar disorders also represent significant treatment needs, while post-traumatic stress disorder, obsessive-compulsive disorder, eating disorders, and substance use disorders have fewer established pharmaceutical options.

Attention deficit hyperactivity disorder is forecast to expand at a CAGR of 9.71% between 2026 and 2031. Growth reflects increased adult diagnosis, including among women and girls who have historically been underdiagnosed. Stimulant supply constraints have increased prescriber interest in non-stimulant options. Takeda expanded the availability of its attention deficit hyperactivity disorder portfolio in several international markets following regulatory approvals in 2025. This development reflects growing commercial focus on pediatric and adult demand outside North America within the mental disorder treatment market.

Complete Report Scope:

• By Treatment Modality
  • Pharmacological Treatment
    • Antidepressants
    • Antipsychotics
    • Anxiolytics and Hypnotics
    • Mood Stabilizers
    • Stimulants
    • Non-Stimulant ADHD Medicines
    • Other Psychotropic Medicines
  • Psychotherapy and Behavioral Treatment
  • Integrated and Community-Based Treatment
  • Neuromodulation and Other Treatment
• By Disorder Type
  • Depressive Disorders
  • Anxiety Disorders
  • Schizophrenia Spectrum Disorders
  • Bipolar Disorders
  • Attention Deficit Hyperactivity Disorder
  • Post-Traumatic Stress Disorder
  • Obsessive-Compulsive Disorder
  • Eating Disorders
  • Substance Use and Addictive Disorders
  • Others
• By Route of Administration
  • Oral
  • Injectables
  • Transdermal
  • Others
• By End User
  • Hospitals
  • Psychiatry Facilities
  • Outpatient Clinics
  • Specialty Mental Health Centers
  • Rehabilitation Centers
  • Home-Based Care
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held a 42.45% regional revenue share in 2025, supported by established reimbursement channels, widespread use of branded psychiatric medicines, and formulary access through employer-sponsored insurance and Medicare. The CMS 2026 Physician Fee Schedule broadened behavioral health telehealth coverage, introduced collaborative care billing codes, and expanded billing privileges for mental health professionals. These measures support pharmacological treatment and psychotherapy delivery. Canada authorized ZURZUVAE for postpartum depression in December 2025, while Mexico remains less penetrated despite expanding urban private insurance coverage.

Europe was the second-largest region in the mental disorder treatment market. Germany provides statutory outpatient psychotherapy coverage, while the United Kingdom operates an NHS-integrated mental health delivery system. The MHRA approved zuranolone for postnatal depression in August 2025, and the European Commission approved ZURZUVAE for postpartum depression in September 2025. France increased psychotherapy session reimbursement from EUR 30 (USD 32) to EUR 50 (USD 54) in May 2025, with Health Insurance covering 60% of costs. Germany supports long-acting injectable antipsychotics, while Italy, Spain, and other markets are expanding capacity at varying rates.

Asia-Pacific is forecast to grow at a CAGR of 10.73% from 2026 to 2031, the fastest regional rate in the mental disorder treatment market. Government-backed digital health infrastructure, broader insurance coverage, and a large untreated mental health burden support access in China, India, and South Korea. Japan’s aging population supports demand for treatments for late-onset depression and Alzheimer’s disease-related psychosis. South Korea and Australia contribute through digital health regulation and platform reimbursement, while the Middle East and Africa remain smaller markets driven by Gulf Cooperation Council investment and South African policy commitments. Brazil and Argentina lead private psychiatric service development in South America.

List of Companies Covered in this Report:

• Abbvie
• Acadia Pharmaceuticals Inc.
• Alkermes plc
• Amneal Pharmaceuticals
• AstraZeneca
• Axsome Therapeutics
• Biogen
• Bristol-Myers Squibb
• Cipla
• Eli Lilly and Company
• GlaxoSmithKline
• H. Lundbeck
• Hikma Pharmaceuticals
• Intra-Cellular Therapies, Inc.
• Johnson & Johnson
• Lupin
• Neurocrine Biosciences
• Novartis
• Otsuka
• Pfizer
• Sage Therapeutics
• Sumitomo Pharma Co., Ltd.
• Sun Pharmaceuticals Industries
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Vanda Pharmaceuticals
• VistaGen Therapeutics, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support